Lamar Alexander @SenAlexander
Clarifying that the makers of brand biological products, such as insulin, are not gaming the system to delay new, lower cost biosimilars from coming to market, from @SenTinaSmith, @SenBillCassidy, and @SenKevinCramer. — PolitiTweet.org